Type6 CDK2 inhibitor

Type6 Therapeutics is developing a small-molecule CDK2 inhibitor as its lead program for the treatment of aggressive tumors. The compound is developed using a proprietary bivalent chemistry platform designed to engage disease-driving kinases in their inactive 'OFF-states' rather than inhibiting the catalytic function of the 'ON-state.' By stabilizing Cyclin-dependent kinase 2 (CDK2) in its inactive conformation, the drug aims to provide superior selectivity, deeper inhibition, and improved durability compared to traditional kinase inhibitors. This approach is intended to prevent tumors from utilizing adaptive escape routes that typically lead to resistance. The program is currently in the IND-enabling stage, specifically targeting cancers characterized by p53 mutations, Ras or PI3K pathway activation, and cMyc amplification.